USP Grade Phenol

In multi-dose injectable products, USP Grade Phenol functions as a preservative at concentrations typically between 2.5 mg/mL and 5.0 mg/mL (0.25–0.5% w/v). The monograph requires an anhydrous assay of 99.0–100.5% and a congealing temperature not lower than 40°C. Phenol is combined with m-cresol in several commercial insulin and peptide hormone presentations because the two preservatives cover overlapping but not identical challenge organisms; m-cresol contributes activity against Pseudomonas aeruginosa, while phenol broadens coverage against fungal spores. Preservative efficacy testing under USP <51> uses Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404. For parenteral products, the bacterial acceptance criterion is not less than 1.0 log reduction from the initial calculated count at 7 days and not less than 3.0 log reduction at 14 days, with no increase from the 14-day count at 28 days; fungal counts show no increase from the initial calculated count at 7, 14, and 28 days. The terminal dosage forms include multi-dose insulin vials, allergen immunotherapy extracts, and sterile diluents for peptide hormones. Phenol is not suitable for intrathecal, epidural, or perineural administration unless deliberate neurolysis is intended; above 5% w/v the compound denatures axonal proteins. For licensed biologicals, preservation must also meet 21 CFR 610.15(a) for multi-dose container systems. Aqueous phenol partitions into elastomeric closures; natural rubber stoppers cause a measurable loss of free phenol within the first 3 months of storage. Chlorobutyl and bromobutyl closures are preferred because their lower unsaturation reduces preservative uptake. Phenol is added before sterile filtration at 0.22 µm where the process train allows.

Table 1. Preservative loading and compendial monitoring matrix.

Phenol-containing parenterals are tested for bacterial endotoxins according to USP <85>; the endotoxin limit for general injectables is calculated from the maximum human dose. Phenol at preservative concentrations does not mask endotoxin activity in the limulus amebocyte lysate assay, so the test can be run on the finished product without chemical interference. In multi-dose formulations, the closure system is selected by conducting accelerated stability studies at 40°C and 75% RH according to ICH Q1A(R2); free phenol is assayed by high-performance liquid chromatography with UV detection at 270 nm because partition into closures and oil phases makes nominal concentration insufficient for shelf-life control.

Topical Anesthetic Compounding, Permeation Enhancers, and the pH-Dependent Activity of Phenol

The local anesthetic effect of phenol in topical formulations is produced by reversible protein denaturation of sensory nerve endings, a mechanism distinct from amide- and ester-type anesthetics. USP Grade Phenol is incorporated at 0.5–1.5% w/v in lotions, sprays, and emulsions for temporary relief of pain and itching. The unionized fraction controls stratum corneum permeation; above the pKa of 9.95, ionization dominates and skin penetration falls sharply, so compounded vehicles are buffered to pH 4.0–5.5. In an oil-in-water emulsion, phenol distributes among the oil phase, aqueous phase, and surfactant interface; the free aqueous concentration is lower than the nominal formula concentration because phenol partitions into the internal oil phase according to the emulsion oil-to-water ratio. This makes it necessary to run antimicrobial effectiveness testing on the final emulsion under USP <51>, and to assay the aqueous ultracentrifugate by high-performance liquid chromatography with UV detection at 270 nm rather than relying on a bulk assay. Phenol is incompatible with strong alkalis, potassium permanganate, hydrogen peroxide, and halogens; contact with strong oxidizing agents generates quinones, and a pink-to-red color change indicates oxidative degradation. Compounded preparations should be packaged in glass or high-density polyethylene containers; phenol permeates some polyolefins, so low-density polyethylene containers are not recommended. The terminal formulation may be a phenol-containing calamine lotion, an otic solution with sodium borate, or a topical spray. On mucous membranes, the concentration should not exceed 0.5% w/v; higher concentrations cause tissue sloughing and pain. Large-area application under occlusion is not recommended because phenol can be absorbed systemically and may cause cardiac arrhythmia after saturation of hepatic glucuronidation and sulfation. Nonsterile compounding is conducted under USP <795>; beyond-use dating is short unless a stability study confirms chemical and microbiological integrity.

When USP grade phenol is used as a starting material for salicylic acid, the process begins with formation of sodium phenoxide by combining molten phenol with 50% w/w sodium hydroxide solution in a jacketed stainless steel reactor. Water is removed under reduced pressure at 80–100°C to a moisture content below 0.5% w/w; residual water shortens the carboxylation step and promotes hydrolysis of downstream sodium salicylate. The dried sodium phenoxide is transferred to a gas-sparged autoclave and contacted with carbon dioxide at 120–140°C and CO2 partial pressures of 5–10 bar. The reaction is continued until carbon dioxide uptake ceases; conversion is monitored by titration of the sodium salicylate intermediate, and the end point is mass-transfer limited. The reactor is equipped with a turbine impeller operating at 200–400 rpm; lower agitation rates create localized para-hydroxybenzoic acid formation due to poor CO2 dispersion. The crude sodium salicylate is dissolved in hot water and acidified with sulfuric acid to precipitate salicylic acid at pH 2.0–2.5, followed by filtration and recrystallization from hot water. USP grade phenol reduces the load of chlorinated impurities and sulfonated by-products that appear when technical-grade phenol is used; residual phenol in the final salicylic acid must be controlled because it can carry forward into acetylsalicylic acid and produce phenol-related impurities during storage. The terminal salicylic acid is then acetylated with acetic anhydride at 75–85°C in a glass-lined reactor, with excess acetic anhydride quenched by controlled addition of water. The critical process limit is the temperature window in the carboxylation step: above 145°C, decomposition of sodium phenoxide increases sharply and the yield of salicylic acid drops, while below 110°C, the reaction rate becomes commercially unacceptable. Published yield data for USP-grade feed in this exact configuration is limited; the main operational control is the absence of water rather than the phenolic assay.

Table 2. Carboxylation process parameter windows for phenol-to-salicylate conversion.

Purification of salicylic acid derived from USP phenol includes recrystallization from hot deionized water with activated carbon; the recrystallized material is dried at 60–70°C to a moisture content below 0.5% w/w. Residual phenol is monitored by gas chromatography with flame ionization detection; a limit of not more than 0.01% w/w is commonly applied to salicylic acid intended for acetylsalicylic acid synthesis. The purified salicylic acid is tested against the relevant USP monograph for assay, residue on ignition, and color. The use of distilled phenol rather than technical-grade phenol does not alter the carboxylation mechanism, but it reduces the burden of cresol-derived isomers in the final salicylic acid and simplifies the recrystallization step.

What Controls Neurolytic Injection Concentration in Glycerin-Based Phenol Systems?

Neurolytic applications of phenol rely on a concentration-dependent destruction of nerve fibers; concentrations below 1% w/v produce reversible anesthesia, while concentrations at or above 5% w/v denature axon proteins and cause Wallerian degeneration. In pain medicine, phenol is formulated at 5–10% w/v in glycerin or sterile water for injection, and the resulting solution is injected in volumes of 0.5–2.0 mL per site under fluoroscopic or ultrasound guidance. Glycerin-based solutions are hyperbaric relative to cerebrospinal fluid, which allows gravity-dependent spread when the patient is positioned; this property is used in intrathecal neurolysis for cancer pain but creates a risk of unintended nerve-root injury if the patient is moved too soon after injection. The preparation must be compounded under USP <797> as a sterile preparation because phenol is not a preservative at neurolytic concentrations. Aqueous phenol diffuses more rapidly and is used for peripheral nerve blocks, while glycerin phenol spreads less and remains localized. Published clinical protocols for lumbar sympathetic neurolysis use 6–7% w/w aqueous phenol; intrathecal saddle block procedures use 5% w/w phenol in glycerin. The operational boundary is strict: intrathecal injection of phenol above 10% w/w has been associated with severe meningeal irritation, bladder dysfunction, and irreversible motor loss. The terminal product is a single-use neurolytic injection; it is not terminally sterilized by steam after compounding because phenol can decompose and discolor, so aseptic filtration through a 0.22 µm membrane is used where the vehicle permits. The resulting preparation must be protected from light and used within 24 h because oxidation to quinones increases neurotoxicity unpredictably. Endotoxin testing under USP <85> is required for intrathecal batches.

Cardiac Monitoring Boundaries Apply When Full-Face Phenol Peels Deliver More Than Three Grams of Phenol

Deep chemical peeling solutions containing phenol are prepared as a two-phase hydroethanolic system, not as a simple aqueous dilution; the Baker-Gordon formulation uses 88% w/w liquefied phenol USP combined with croton oil and a hexachlorophene-based soap. The mixture separates on standing and must be swirled immediately before application to prevent localized high-concentration phenol streaks. Phenol causes immediate coagulation of epidermal proteins, which limits its own penetration; croton oil is added to disrupt the coagulum and permit a deeper peel. During a full-face phenol peel, the total applied phenol dose can exceed 3 g, and systemic absorption is rapid enough to require continuous cardiac monitoring, intravenous hydration, and pulse oximetry for the entire procedure. The liver metabolizes phenol by conjugation to glucuronide and sulfate; saturation of this pathway can lead to ventricular arrhythmia, so the procedure is contraindicated in patients with hepatic or renal impairment. The applied volume is typically limited to 1.0–1.5 mL per aesthetic unit, and the full face is treated in 30–60 min to avoid a bolus effect. The terminal result is controlled exfoliation of the papillary dermis and regeneration of collagen; the patient must be monitored for 45–60 min after the procedure. USP grade phenol is used because industrial-grade phenol contains cresols and sulfur impurities that worsen post-peel hyperpigmentation. The solution is compounded immediately before use under medical supervision; activated charcoal and antiarrhythmic drugs must be available in the procedure room. This use is not a conventional pharmaceutical dosage form and is governed by institutional protocols rather than USP <795>.

Acidic phenol extraction for RNA isolation requires equilibration of the organic phase with citrate or acetate buffer at pH 4.3–4.7; under these conditions RNA remains in the aqueous phase while DNA and proteins partition into the phenol-chloroform interphase or organic layer. For DNA extraction, the phenol is equilibrated with Tris-EDTA at pH 7.8–8.0, which retains DNA in the aqueous phase while proteins are denatured. USP Grade Phenol can serve as the starting material after distillation and saturation with the appropriate buffer, but the as-received USP monograph does not test for DNase or RNase activity. The organic phase is typically mixed with chloroform and isoamyl alcohol at a 25:24:1 ratio for DNA or a 50:48:2 ratio for RNA, and phase separation is achieved by centrifugation at 12,000 × g for 15 min at 4°C. RNA is precipitated from the aqueous phase with isopropanol in the presence of sodium acetate; DNA is precipitated with ethanol. The terminal products are purified total RNA or genomic DNA for reverse transcription–quantitative polymerase chain reaction, microarray hybridization, and next-generation sequencing. The operational boundary is that oxidized phenol containing quinones degrades nucleic acids and reduces yield; phenol that has turned pink must be redistilled under nitrogen before use. Published data for substitution of USP grade phenol in nucleic acid extraction is limited, so each lot should be validated by measuring RNA integrity number on a bioanalyzer and spectrophotometric A260/A280 ratios between 1.8 and 2.0 for RNA, and between 1.7 and 1.9 for DNA. Extraction must be performed in a chemical fume hood because phenol is corrosive and volatile. This application is not a pharmaceutical manufacturing process and is outside the scope of USP <795>; it is governed by internal laboratory standard operating procedures.

When Phenyl Salicylate Synthesis Replaces Direct Salicylic Acid Esterification

Phenyl salicylate, known as salol, is synthesized from USP grade phenol and salicylic acid at a molar ratio of 1.5–2.0:1 phenol to salicylic acid, using a catalytic amount of phosphorus oxychloride or concentrated sulfuric acid. The reaction is run under reflux at 150–160°C in a glass-lined reactor with a Dean-Stark trap for water removal; excess phenol is used to shift equilibrium and is later recovered by distillation. The molten product is washed with dilute sodium carbonate solution to remove unreacted salicylic acid, then recrystallized from ethanol to a melting point of 41–43°C. Phenyl salicylate is used as an ultraviolet absorber in topical formulations and as a chemical intermediate for analgesics and antipyretics. The critical quality attribute is absence of free phenol; the recrystallized product is assayed for free phenol by gas chromatography with a limit of not more than 0.1% w/w. The reaction mass must be kept anhydrous because water hydrolyzes phenyl salicylate back to phenol and salicylic acid, reducing yield. The use of USP grade phenol minimizes cresol and chlorophenol impurities that would otherwise form phenyl cresol esters with different melting points and dermatological irritation profiles. The terminal product is a white crystalline solid that is slightly soluble in water and freely soluble in ethanol; it is packaged in amber glass to prevent photochemical yellowing. Melting range is confirmed according to USP <741>.